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A B S T R A C T
Viral diseases represent one of the major threats for salmonid aquaculture. Survival from viral infections are
highly dependent on host innate antiviral immune defense, where interferons are of crucial importance.
Neutralizing antibodies and T cell effector mechanisms mediate long-term antiviral protection. Despite an im-
mune cell repertoire comparable to higher vertebrates, farmed fish often fail to mount optimal antiviral pro-
tection. In the quest to multiply and spread, viruses utilize a variety of strategies to evade or escape the host
immune system. Understanding the specific interplay between viruses and host immunity at depth is crucial for
developing successful vaccination and treatment strategies in mammals. However, this knowledge base is still
limited for pathogenic fish viruses. Here, we have focused on five RNA viruses with major impact on salmonid
aquaculture: Salmonid alphavirus, Infectious salmon anemia virus, Infectious pancreatic necrosis virus, Piscine
orthoreovirus and Piscine myocarditis virus. This review explore the protective immune responses that salmo-
nids mount to these viruses and the existing knowledge on how the viruses counteract and/or bypass the immune
response, including their IFN antagonizing effects and their mechanisms to establish persisting infections.
1. Several paths to antiviral defense
Viruses outnumber other microbes in the aquatic environment, and
fish are constantly bombarded with them [1]. With that in mind, it is
not surprising that some of the most common health threats for sea-
water aquaculture are viral diseases. Moving aquaculture from the sea
to closed recirculating aquaculture system (RAS) facilities may solve
the direct contact between aquaculture cages and the pathogens of the
ocean. However, viruses can adapt to and establish themselves in closed
facilities, and new viruses can emerge in the new environment. It is
likely that viral infections in aquaculture will continue to be a sig-
nificant future challenge.
With the constant exposure of farmed fish to this viral burden, their
antiviral immune system needs to be alert and functioning. Effective
vaccines are obvious solutions to the viral threat, but vaccines fail if the
pathogenic viruses mutate, if new disease-causing viruses emerge, or if
the immune system is suppressed. By use of various tactics, viruses are
experts in hiding from immune detection and dampening host defense.
Emerging pathogenic viruses possess the most successful immune eva-
sion strategies, and the fish need to counteract the viral strategies in
order to survive. To ensure that farmed fish are genetically equipped,
adequately vaccinated and optimally prepared for antiviral defense, we
need to understand the specific interplay between virus and host in
depth.
Fish are covered with mucosal tissue, which is where the first en-
counter between virus and host occur. Mechanisms like mucus shedding
and reproduction, antiviral peptides and enzymes, but also mucosal
antibodies, act to fight pathogens in the mucus layer [2,3]. Details of
the mucosal immune system have been thoroughly reviewed elsewhere
[2–4], and will only be touched upon for certain viruses here.
In fish, like in mammals, the center of the antiviral innate immune
mechanism in internal organs is focused around type I interferon (IFN)
production and its actions as a secreted “early warning” signal from the
infected cell to cells in the tissue environment [5–7]. IFN production is
triggered by binding of viral nucleic acids to either Toll-like receptors
(TLRs) in the endosomes or plasma membrane, or to cytoplasmic re-
ceptors, mainly within the RIG-like (RLR) receptor family [8]. Viral
glycoproteins can also be recognized by pattern recognition receptors
(PRRs), and it has been speculated that the G protein of rhabdoviruses
binds to a glycoprotein recognizing PRR [9,10]. All these receptors
trigger activation of IFN response factors (IRFs) to induce IFN pro-
moters. IFN type I variants in fish differ between species, and details of
salmonid IFNs are well covered elsewhere [6,7,11]. The IFNs are se-
creted to act on IFN receptors resulting in activation of a downstream
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signaling cascade that induces a large number of interferon-stimulated
genes (ISGs) that confer direct antiviral activities to counteract further
virus dissemination in the host. Most pathogenic viruses have evolved
to develop specific mechanisms that bypass or block IFN production,
and/or interfere with the IFN receptor-mediated activation of ISGs or
the ISGs themselves. In salmonids, and most likely in other fish species,
the numerous nucleated red blood cells population also play an im-
portant systemic role in mediating the antiviral innate immune re-
sponse [12,13].
Whereas the general mechanisms for IFN-mediated antiviral innate
immunity are well conserved in vertebrates [11], the execution of
adaptive immune responses differ more between fish species and other
vertebrate groups [14]. As the first vertebrate group that possesses all
elements of adaptive immunity, the teleosts lack lymph nodes, follicular
structures and do not form germinal centers, which are the specialized
lymphoid structures in higher vertebrates [14]. Instead, recruitment of
immune cells to the site of infection is important for initiating the
adaptive response.
Except from some very primitive examples, vertebrate fish have IgM
as their main systemic antibody, IgD at low expression levels, and IgT as
a dominating antibody at mucosal surfaces [15], but not exclusively so
[16]. Salmonids develop specific, often neutralizing, antibody re-
sponses to viral infections [17]. The B cells in salmonids have main-
tained some innate functions, like phagocytosis [18] and expression of
PRRs including TLRs [19,20], suggesting that fish B cells resemble
mammalian B-1 cells more than B-2 cells [21,22]. In line with this,
IgM + B-cells from teleost fish express the B-1 marker CD5 [23]. For T
cells, differences between fish species are more evident. While cod
completely lack MHCII and CD4 T cells [24], salmonids have T cell
immune functions resembling their mammalian counterparts, including
both cytotoxic (CD8+) and helper (CD4+) T cells, and corresponding
MHCI and MHCII [25,26]. Typical cytokines linked to Th polarization
are also present, exemplified by the Th2 cytokines IL4/IL13 [27]. A
pending question is still how Th cells are related to B cell activation in
different fish species.
The innate and adaptive immune equipment of teleost fish should
lay the ground for producing effective vaccines that trigger both hu-
moral and cellular immune defense. Despite this, the long-term effects
of several virus vaccines have not been optimal, and the answers may
lie in the characteristics of the viruses that have emerged in salmonid
aquaculture, and/or their ability to avoid immune surveillance.
2. Five RNA-viruses and their strategies to circumvent antiviral
defense
Five RNA viruses have had major impact on Atlantic salmon farming
by causing frequent or high mortality disease: Salmonid alphavirus
(SAV) and infectious salmon anemia virus (ISAV) are lipid membrane
enveloped, single stranded (ss) RNA viruses, whereas Infectious pan-
creatic necrosis virus (IPNV), Piscine orthoreovirus (PRV) and Piscine
myocarditis virus (PMCV) are naked, double stranded (ds) RNA viruses
[28–31]. All five viruses belong to different virus families (Table 1).
Through studies on infection strategies and host interplay for these
viruses, important aspects of teleost antiviral defense have been un-
raveled. Here, we describe the status of knowledge on the virus-host
interaction pattern for each of them. This includes existing knowledge
on virus receptors and sensors, their target cells and tissues, the IFN
response and downstream activation of antiviral effector proteins. Next,
we have looked into timing and localization of the humoral and cellular
arm of the adaptive immune response elicited by viral infections. Large
–omics studies have to some extend helped us understand virus stra-
tegies, immune responses and development of disease (Table 2). As our
knowledge of the teleost immune system expands, a more detailed
understanding of fish-virus interactions will develop. In this review, we
point out some research gaps that, if answered, would enable a more
elaborative understanding of immunity to fish viruses.
2.1. Salmonid alphavirus (SAV)
Salmonid alphavirus, also referred to as Salmon Pancreas Disease
Virus (SPDV), is a significant pathogen for Atlantic salmon and rainbow
trout in Europe. SAV is the causative agent of pancreas disease (PD)
affecting Atlantic salmon or sleeping disease (SD) affecting rainbow
trout. The latter was initially reported for fresh-water reared trout in
France [32], but SD in trout has since then been described in several
continental European countries [33], and more recently Poland and
Switzerland [34,35]. PD is found throughout Europe including Norway,
UK, Ireland, France, Italy, and Spain [27]. SAV causes lethargy and
anorexia of the infected fish, leading to slow growth and runting [36].
Significant mortality rates (up to 60%) have been observed in PD out-
breaks [37], and the disease is a major economical and welfare problem
for farmed salmon in Europe. Despite vaccination programs, SAV is
becoming increasingly predominant in the field and the eradication of
this pathogen is a challenge for most fish farms.
2.1.1. Subtypes and genome
Based on differences in the E2 and nsP3 genes, SAV strains are
grouped into 6 different subtypes, SAV1-6 [38]. SAV1, first isolated
from Atlantic salmon, is the causative agent of PD in Ireland and
Scotland [39]. SAV2 comprises two subgroups, a freshwater variant
(SAV2-FW) causing SD in trout, and a marine variant (SAV2-MW) re-
sponsible for PD in seawater reared salmon and rainbow trout [33].
SAV3 is a Norwegian subtype and affects both Atlantic salmon and
rainbow trout [40,41]. The subtypes 4–6 are found in Atlantic salmon
from overlapping areas of the coast of Ireland, Northern Ireland and
Scotland [36]. The focus of this review will mainly be on SAV1, SAV3
and PD.
SAV belongs to the genus Alphavirus in the family of Togaviridae
[39,42]. Alphaviruses have ssRNA genomes with positive polarity en-
closed in an enveloped icosahedral nucleocapsid [43] (Table 1). The 5′
two-thirds of the nearly 12 kb genome encode the non-structural pro-
teins nsP1-4, which comprise the viral components required for re-
plication of the viral genome and for the transcription of subgenomic
RNA. The 3’ one-third of the genome contains subgenomic RNA, which
translates into the structural capsid proteins (E3, E2, 6K, TF, and E1)
that form the virus particle. Knowledge of the determinants for SAV
virulence is limited. A reverse genetics system for SAV2 was developed
by INRA France [44] and has enabled identification of mutations within
the E2, 6K and E1 proteins associated with virulence in rainbow trout.
Later a reverse genetic system was reported for SAV3 [45], which al-
lows functional studies into the virulence determinants of SAV3 as well
[46].
2.1.2. Tissue tropism and pathogenesis
SAV has a wide tissue tropism in Atlantic salmon [47], however,
heart, skeletal muscle, and pancreas are the organs mainly affected by
PD and SD and descriptions of the pathology associated with the disease
are described in detail elsewhere [37,41]. The histopathology for these
diseases are sequential where the pancreatic lesions appear first after
infection, followed by heart muscle lesions and finally extensive lesions
of skeletal muscle fibers. By using both in vivo and in vitro models,
Biacchesi et al. [48] reported that muscle satellite cells are targets for
SAV2 infection in rainbow trout. Virus replication was detected in ex
vivo cultivated satellite cells [48]. Together with the loss of exocrine
pancreas leading to defective uptake of nutrients, this may explain the
reduced muscle growth observed in surviving SAV-infected fish [37].
2.1.3. Innate immunity
For alphavirus species in higher vertebrates, type I IFN-dependent
innate immune response is essential for protection [49]. IFN receptor
deficient mice are highly susceptible to alphavirus infections signifying
the importance of IFN-mediated defence [50]. The ability of IFNs to
restrict viral replication in vertebrate cells is largely mediated trough
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the induction of ISGs and a subset of ISGs have been shown to impede
alphavirus replication in mammals [50]. In line with this, up-regulation
of type I IFNs and ISGs during SAV challenges in salmonids are reported
[51–56]. Two microarray studies are performed for SAV1 challenged
trout [57] and SAV3 challenged salmon [53] (Table 2), using head
kidney and heart, respectively. Despite different target organs, pro-
found induction of ISGs including Mx, Viperin, ISG15, and several IFIT
and GIG family member genes were demonstrated for both SAV sub-
types. By using SAV3-infected TO cells, increased TLR3/8, MDA5, RIG-
I, and LPG2 transcription were shown [58,59] suggesting that TLR and
RLR pathways are involved in SAV recognition and signaling. In both
studies, LPG2 and RIG-I in the SAV3 infected cells were more highly
upregulated than MDA5. The RLRs are RNA helicases that signal
through the adaptor molecule MAVS/IPS1 to activate the transcription
factors IRF3, IRF7 and NF-kB, driving transcription of proinflammatory
cytokine genes including type I IFN encoding genes [60]. The mam-
malian alphavirus chikugunya (CHIKV) is RLR restricted as MAVS de-
ficient mice have increased viremia and show reduced IFN levels in
serum [50]. Studies of mice deficient for TLR7 or TLR3, as well as their
adaptor molecules MyD88 and TRIF, suggest that TLR signaling also
contribute to control CHIKV infection, as these mice show increased
viremia and enhanced dissemination compared with wild type [50].
Several in vivo studies have demonstrated the induction of TLRs and
the adaptor molecule MyD88 [52,61] as well as the RLRs MDA5 and
LGP2a [55] in SAV-infected salmonids. In the study by Moore et al.
[55], these PRRs showed an earlier peak response in the head kidney
for SAV3 intramuscular injected fish compared to bath challenged fish.
Grove et al. [52] reported induced levels of TLR8 mRNA in salmon head
kidney, heart and gills derived from SAV3 fish challenged by cohabi-
tation, while in another study of SAV3 ip injected fish, TLR8 mRNA
levels in spleen were unaffected [61]. In the latter study, MyD88
transcripts remained unchanged at day 3, while at day seven and 28
post SAV injection their levels were four-fold upregulated compared to
untreated controls. In recent studies, up-regulation of both TLR7 and
TLR8 in SAV3 bath-challenged salmon were reported, where TLR7 was
more highly induced than TLR8, while TLR8 showed higher con-
stitutive levels [55]. Collectively, the findings illustrate that the chal-
lenge route is of importance for the onset and duration of innate re-
sponses, and that bath immersion challenges induce lower and more
sustained responses compared to injection challenges [55]. Reduced PD
pathology and SAV levels in salmon injected with the TLR-ligands poly
I:C or CpG, correlating with up-regulated levels of both type I IFN, IFNγ
and Mx are found [62]. The study points to importance of the IFNs for
host defence against SAV. This is supported by data showing a direct
antiviral effect of salmon IFNa1 against SAV3 in cell lines [63,64].
However, while the study by Xu et al. [63] did not detect antiviral
activity upon IFNγ treatment of TO cells, Sun et al. [64] showed potent
antiviral activity against SAV3 by IFNγ in the same cells. In the
presence of anti-IFNa1 antibodies, the antiviral activity of IFNγ was
reduced, proposing that the antiviral activity is partly dependent on
type I IFN-induction [64].
2.1.4. Adaptive immunity
Atlantic salmon or rainbow trout surviving PD outbreaks are less
susceptible to further infection, as observed experimentally or in the
field [65,66]. This shows that salmonids develop an efficient adaptive
immune response against SAV following a primary exposure. The de-
tection of neutralizing antibodies associated with protective responses
against PD suggests involvement of antibody mediated immunity
[67–70]. Passive immunization of SAV in live fish is also reported,
providing evidence that these antibodies are protective [71]. For
mammalian alphaviruses, antibodies directed against the glycoprotein
E2 are often more neutralizing than antibodies reactive to E1 [41].
Recently, Jenberi et al. documented strong anti-E2 responses in SAV3
infected salmon, confirming the reactivity directed against this viral
protein for salmon B cells as well [72]. By using a SAV3 replicon, Hikke
et al. [46] showed the importance of E1 and low temperature, for virion
formation and proper E2 cell surface expression.
The complement system has key roles for the protection against
alphavirus infections by stimulating adaptive responses through anti-
body mediated neutralization of the virus, as well as causing opsoni-
sation of viral particles and complement-dependent lysis of viral in-
fected cells [43]. In general, the role of complement in the protection
against PD is scarcely described, although a few reports suggest its
importance [73,74]. In a study revealing the serum proteome of SAV3-
infected salmon (Table 2), the complement components C3, C9, com-
plement factor B and H and the complement inhibitor C1 were identi-
fied [73]. C9 is an important component of the complement-membrane-
attack-complex (MAC) known to lyse enveloped viruses. In another
study, increased levels of C4, an important factor for classical compo-
nent activation, were shown in sera from SAV-infected salmon [74]. In
the same study, C4 levels were depleted in SAV-vaccinated groups,
which showed protection against PD. The consumption of C4 is a sen-
sitive measure of classical activation, suggesting a role of antibody
mediated complement activation in protection against piscine alpha-
viruses.
T cell associated genes including CD8α, CD3z/b, CD4-2 and CD40
are shown to be up-regulated following SAV3 infection in heart
[51–53], head kidney [51,52], spleen [51], pancreas [51], gills [52],
and also by SAV whole virus vaccination [68–70]. In general, the ex-
pression levels of these genes were moderately affected in the im-
munological organs; gills, spleen and head kidney, and they were
shown to decline over time. In contrast, CD4, CD8, CD3ε, MHCII and IL-
12 levels were, in general, higher in the primary target organs heart and
pancreas at later time points (6–8 weeks) [51,52], which also correlated
with the highest IgM mRNA and antibody levels. The results suggest
Table 1
Description of five salmonid viruses, their structure, genome and associated diseases.
Virus Family Structure Genome (segments) Variants, diseases and target species
Salmonid alphavirus SAV Togaviridae Enveloped
Spherical, icosahedral single capsid
∼70 nm
+ssRNA (1) SAV1,2,3: Pancreas Disease (PD) in Atlantic salmon
SAV2: Sleeping disease (SD) in rainbow trout
Infectious salmon anemia virus ISAV Orthomyxo-viridae Enveloped ellipsoidal single capsid
∼100 nm
-ssRNA (8) ISAV HPRdel: Infectious salmon Anemia (ISA) in
Atlantic salmon
Infectious pancreatic necrosis virus
IPNV
Birnaviridae Non-enveloped
Icosahedral single capsid ∼70 nm
dsRNA (2) Infectious pancreatic necrosis (IPN) in Atlantic
salmon
Piscine orthoreovirus PRV Reoviridae Non-enveloped icosahedral double
capsid ∼80 nm
dsRNA (10) PRV-1: Heart and skeletal muscle inflammation
(HSMI)-Atlantic salmon
PRV-2: Erythrocyte inclusion body syndrome (EIBS)
in Coho salmon
PRV-3: HSMI-like disease w/anemia in rainbow trout
Piscine myocarditis virus PMCV Totiviridae Non-enveloped icosahedralS single
capsid ∼40 nm
dsRNA (1) Cardiomyopathy syndrome (CMS)
Atlantic salmon
M.K. Dahle, J.B. Jørgensen Fish and Shellfish Immunology 87 (2019) 421–437
423
that a combined cytotoxic and Th1 mediated response takes part in the
heart at late phases of the infection. Immunohistochemistry on hearts
from salmon from a natural PD outbreak has verified an influx of im-
mune cells, dominated by CD3+ T lymphocytes [75]. The presence of
MHCII expressing cells with macrophage or lymphocyte morphology in
the infected hearts suggest trafficking of immune cells with antigen
presenting capacity i.e. macrophages, DC cells or B cells. While a Th1/
cytotoxic response associated with inflammation/pathology appeared
late (8 weeks) in the SAV ip injected salmon, the reaction in the pan-
creas was greatly downscaled suggesting a contraction phase [51].
Together, the published studies suggest that both humoral and cellular
adaptive responses contribute to the protection against these viruses.
Presently, there is limited understanding of the role T cells play during
alphavirus infection with most work focusing on gene expression and a
lack of studies focusing on cell-mediated cytotoxicity.
2.2. Infectious salmon anemia virus (ISAV)
ISAV, first described as the virus that causes Atlantic salmon anemia
(ISA) in 1995 [76], causes an acute high mortality disease in Atlantic
salmon and has been responsible for high loss epidemics with devas-
tating economic consequences for aquaculture, primarily in Chile in
2007 when ISA outbreaks hampered the planned aquacultural expan-
sion [77,78]. The disease ISA is characterized by severe anemia and
organ necrosis linked to collapsed circulation and gas exchange, in part
induced by red blood cell agglutination [31,77,79,80]. Many wild sal-
monids are also susceptible to ISAV infection, but no disease have been
found in the wild [81].
Table 2
Transcriptomic and proteomic studies describing innate and adaptive immune responses in Atlantic salmon infected with salmonid alphavirus (SAV), infectious
salmon anemia virus (ISAV), infectious pancreas necrosis virus (IPNV), Piscine orthoreovirus (PRV) and Piscine myocarditis virus (PMCV). wpc; weeks post challenge
(for cohabitation), wpi; weeks post infection, dpi; days post infection, I.p.; intraperitoneal, I.m.; intramuscular.
Infection Challenge model Target tissue Immune
system
Analysis Reference Main discovery
SAV I.p. injection Head Kidney Innate Microarray Herath et al. 2012 [57] • Up-regulated IFN mediated/antiviral responses• Up-regulated MHC class I and II pathway genesSAV1
2–5 dpi
Cohabitation Serum Humoral Proteomics Braceland et al. 2013
[242]
• Complement factors dominate early, then decline when
antibodies sharply rise at 5 wpc
• Correlation of tissue injury with creatine kinase, enolase and
malate dehydrogenase during peak PD






Microarray Johansen et al. 2015
[53]
• Up-regulated IFN-mediated responses• MHCII gene expression increases in concert with PD development• Lowly adaptive immune gene expression within the PD trial period
SAV-3
2,5-5 wpc






et al. 2015 [270]
• Up-regulated IFN-mediated responses in all tissues• Up-regulated Be and T-cell gene transcript levels, primarily in
head kidney
• Immune cell migration genes in gills and liver
HPR7b ISAV
3–14 dpc
Cohabitation Spleen Adaptive RNASeq Dettlef et al. 2017 [98] • Viral susceptibility associates with differences in immune gene




IPNV Immersion IPNV Head Kidney Innate
adaptive
Microarray Skjesol et al. 2011 [246] • Early innate antiviral response and IFNγ expression differ
between infections with the virus genotypes(NFHeAr/NFH-
El)
6–29 dpi
Immersion Head kidney Innate,
adaptive
Microarray Reyes-Lopes et al. 2015
[271]
• Susceptible individuals are characterized by a short-lasting,
inflammatory innate response
• Protected individuals have lower and more sustained innate
antiviral immune responses




Immersion Whole fry Innate,
adaptive
Microarray Robledo et al. 2016
[272]
• Susceptible individuals are characterized by high early innate
immune response





PRV Cohabitation Erythrocytes Innate Microarray Dahle et al. 2015 [13] • Long-lasting innate immune response parallels induction of
genes related to antigen presentation and antibody productionPRV-1-Nor
5–10 wpc
I.p injection Heart Innate
Adaptive
Microarray Johansen et al. 2015
[53]
• Long-lasting IFN-regulated antiviral response up to 11 wpc• Adaptive immune responses, dominated by Be and cytotoxic T-







Microarray Johansen et al. 2016
[205]
• Infected parr show earlier induction of genes involved in innate
antiviral immunity compared to smolt




PMCV I.p injection Heart Innate,
Adaptive
Microarray Timmerhaus et al. 2011
[13]
• Systemic induction of antiviral- and IFN-dependent genes from 2
wpi
• Cardiac activation of complement genes prior to cardiac-specific
upregulation of T cell response genes
2–12 wpi
I.p. injection Heart Innate
Adaptive
Microarray Timmerhaus et al. 2012
[273]
• Earlier activation of NK cell-mediated cytotoxicity and NOD-like
receptor signaling pathways in CMS low responder hearts
• Induced T cell response genes in high responder hearts reflect
increased CMS pathology
2–10 wpi
I.m injection Heart Innate,
adaptive
Microarray Martinez-Rubio et al.
2014 [274]
• Functional feeds reduce CMS pathology, associated with lower
expression of genes associated with cytotoxic T-cells6–14 wpi
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2.2.1. Subtypes and genome
ISAV belong to the family of Orthomyxoviridae, and is related to the
mammalian influenza virus [82]. ISAV is an enveloped virus with a
segmented ssRNA genome [79] (Table 1). Both the influenza virus and
the ISAV genome can mutate, recombine and reassort, giving it nu-
merous possibilities to change [82,83]. ISAV exists as an initially
harmless wild-type strain, the so-called highly-polymorphic region
(HPR) 0 strain, which has not been associated with mortality or disease
[84]. The presence of ISAV HPR0 is a potential risk factor for disease,
since mutation into pathogenic strains can cause ISA [85–88]. Two
glycoproteins in the virus envelope, the hemagglutinin esterase protein
(HE) and the fusion protein (F) are essential for virus uptake [89]. ISAV
pathogenicity is related to a diverse set of deletions in the HPR-region
of the HE protein (known as HPRdel), combined with mutation in the F-
protein [87,89–91]. The HPRdel variants, commonly numbered HPR1-
x, show different levels of pathogenicity.
2.2.2. Tissue tropism and pathogenesis
The pathogenesis of ISAV have been previously reviewed [31]. ISAV
uses 4-O-acetylated sialic acids as attachment sites or receptors
[92–97]. A transcriptome study on Atlantic salmon families with dif-
ferential resistance to ISAV revealed that the resistant family (> 35%
less mortality and lower virus levels) showed upregulated expression of
sialic acid-binding Ig-like lectin (siglec14) (Table 2), which may aid
virus binding to 4-O-acetylated sialic acids [98]. Siglec14 is also shown
to be an immune cell stimulator [99,100]. Increased expression was
also observed for epithelial catherin (cdh1), which has been linked to
resistance against IPNV as well [101].
The HPR0 strain primarily infects the gill and skin epithelial cells
and replicates at low levels with no pathological consequences [102]. In
contrast, virulent ISAV establishes a systemic infection, infects en-
dothelial cells, and bud virus into the blood stream [92].
Atlantic salmon experimentally infected through ip injection or
bath/immersion of pathogenic ISAV variants, like the Chilean HPR7b
strain, develop ISA in approximately 10–15 days causing 70–100%
mortality within the following month [98].
2.2.3. Innate immunity
The high mortality from ISAV infections indicates that the immune
system is unable to control and limit the virus replication. There is an
intricate interplay between the IFN system and ISAV replication.
Whereas type I IFNs, more specifically IFNa1 and IFNc, inhibit ISAV
replication [103], at least two ISAV-encoded proteins exhibit type I IFN
antagonist properties [104,105] (Fig. 1). The segment 7-encoded
s7ORF1 is a cytoplasmic protein that inhibits activation of both IFN and
Mx transcription [104,105]. The segment 8-encoded s8ORF2 is located
in the nucleus, binds dsRNA and polyadenylated ssRNA, act as an RNA
silencing suppressor [106], and inhibit poly (I:C)-mediated IFN pro-
moter activation [104].
A comparison between low and high virulent ISAV strains using
mucosal bath challenge revealed that the low virulent ISAV initiated an
earlier IFN-mediated response in the gills, heart and kidney, compared
to the high virulent variant which had a slower response pattern [107].
This gives the immune system a head start in developing a specific
immune response against the low virulent virus. In line with this, the
most virulent ISAV variant also inhibited Mx production more effi-
ciently in cell culture compared to low virulent strains [103].
The related influenza virus mechanisms of interaction with IFN
production and signaling have been thoroughly studied. The multi-
functional NS1 protein interacts with several intracellular proteins es-
sential for initiating the antiviral immune responses [108], and thereby
interfering with the activation of RIG-I, the NF-κB signaling pathway
[17], the stress granule-mediated antiviral activity [18], cell survival
pathways and cellular transcription-translation [27–30]. Several of the
other influenza proteins interact with antiviral proteins as well, but not
to the same extent [108]. Whether ISAV possess a similar entity to
inhibit IFN and ISG production, and if the ISAV proteins are equally
multifunctional are presently a pending question.
2.2.4. Adaptive immunity
Several vaccines against ISAV have been tested in immunization
trials with good results [109–111]. In these studies, the protection has
been closely associated with ISAV-specific and neutralizing antibodies
indicating an important role of humoral immunity in protection. When
focusing on genes associated with ISAV resistance, a role of T cells in
immune protection against ISAV was indicated [98]. The transcription
factor human immunodeficiency virus type I enhancer binding protein
2 (hivep2), which have previously been identified as a potential pro-
tective quantitative trail locus (QTL) for ISAV resistance [112], was
induced in a transcriptome study on ISAV resistant salmon [98].
Hivep2, also known as Shnappi 2, is a lymphocyte transcription factor
shown to be involved in Th2 differentiation [113]. Furthermore, Per-
forin 1-like protein (prf1) which is involved in activity of cytotoxic T
cells was also induced in ISAV resistant fish, indicating antiviral cyto-
toxic immune activity against ISAV [112]. In line with this, a larger
CD8+ population at early stages of infection have been reported in
tissues from salmon infected with a virus strain with low virulence,
compared with the high virulent strain [114]. Taken together, these
observations indicate that both T helper and cytotoxic T cell activity are
protective towards ISAV infection. However, the T cells have to appear
early and act strongly enough to control the virus. Since innate antiviral
responses may be inhibited by ISAV segment 7 and segment 8 proteins,
and neutralizing antibodies may be induced too late to fight ISAV in the
critical phase, T cell-mediated responses may be crucial. However, this
warrants further investigation.
2.3. Infectious pancreatic necrosis virus (IPNV)
Infectious pancreatic necrosis (IPN) is caused by IPNV. IPNV be-
longs to the genus Aquabirnavirus within the family Birnaviridae
(Table 1). Aquatic birnaviruses have a worldwide distribution and are
detected in more than 30 different families of fish [115]. Some hosts are
subclinically infected, while in other hosts the viruses cause disease,
such as IPN in salmonids [115]. Susceptibility of salmonids to IPNV is
age dependent [116], and outbreaks are most often observed in fry
during the freshwater stage, in post-smolts up to 10 weeks after transfer
to sea, and in larger sea-reared salmon [116,117]. IPN has a history as
one of the major loss factors in international salmonid aquaculture.
Vaccines against IPN were introduced into aquaculture in the mid-90s,
but they were not as efficient as the vaccines against bacterial diseases,
which made the control of IPN a challenging task for the fish farmers.
Breeding of salmon that are resistant to IPN has been a success and is
proposed to be the main reason for the dramatic decline of IPNV out-
breaks in Norwegian aquaculture after 2009 [118]. Genetic mapping of
QTLs affecting disease resistance against IPN has made it possible to
produce IPN resistant salmon for the aquaculture industry [54]. The
epithelial protein cadherin (CDH1) has been linked to this resistance
[101]. This protein strongly binds to IPNV virions, and co-localization
between the virus and CDH1 in endosomes indicates that the protein is
involved in IPNV internalization [101].
2.3.1. Subtypes and genome
Birnaviruses possess a bi-segmented dsRNA genome, designated
segment A and B that is enclosed in a non-enveloped single-shelled
icosahedral particle about 60 nm in diameter [119]. VP1, the viral RNA-
dependent polymerase encoded by segment B is the largest of the viral
proteins (94 kDa) [120]. Segment A has two overlapping open reading
frames, of which the smaller encodes VP5 and the larger encodes a 103-
kDa polyprotein [121,122]. After its translation, the polyprotein is
cleaved and further processed to form the mature outer capsid protein
VP2, in addition to VP3 and VP4. VP3 is the suggested key organizer of
particle assembly in birnaviruses and is shown to interact with VP1 and
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ds-RNA [123]. Nucleotide sequence analyses of IPNV isolates differing
in pathogenicity have revealed that VP2 is a major determinant of
virulence for the virus. There is experimental evidence showing that
viruses of the Sp strain encoding Thr217-Ala221 are highly virulent,
while isolates encoding Pro217-Ala221 are moderately virulent and
Pro217-Thr221 isolates are classified as avirulent [124,125]. However,
conflicting data exist which describe strains with Pro217-Ala221 to be
highly virulent both in experimental conditions and in the field
[126,127].
2.3.2. Tissue tropism and pathogenesis
Both gills and intestine are suggested as routes of entry for IPNV. As
the name implies, IPNV primarily affect the pancreas and the most
consistent histopathological finding is necrosis of exocrine pancreatic
tissue [128]. Necrosis in other organs, e.g. liver, gut and hematopoietic
tissues are also common findings [129].
2.3.3. Persistence
Fish that survive IPN outbreaks may become persistently infected,
and the virus is likely to persist by subverting the host defence for a
long time, even throughout their lives [130]. The virus has been re-
ported to hide and multiply within head kidney derived leucocytes from
carrier fish without causing lytic infection, suggesting that these cells
could be a site of persistent infection [131–135]. While Sommer &
Johansen [133] reported a low IPNV replication rate in head kidney
macrophages derived from infected fish, a separate study found it to be
non-detectable [136]. In addition to macrophages, IPNV is detected in
head kidney derived neutrophils and B cells originating from IPNV
challenge survivors, suggesting that these cells are potential targets for
IPNV infection [135]. Santi et al. [137] have implied that IPNV strains
differ in their ability to establish persistent IPNV infections. The authors
suggested that Thr residue 221 is a prerequisite for persistent infections,
while strains with Ala at this position did not establish long-term per-
sistent infections as efficiently as the avirulent virus. Later, Julin et al.
[138] showed that both virulent and avirulent strains cause persistent
infections. In their study, infections with both the strains were followed
at freshwater and seawater phases. In freshwater, higher levels of IPNV
transcripts were detected in head kidney of fish infected with low
virulent compared to high virulent virus, suggesting that the latter is
able to limit its own replication to a level where the innate response is
not alerted [138]. When ex vivo cultivated adherent leukocytes were
stimulated with the TLR ligand CpG, known to induce the IFN pathway
in these cells [139], significantly higher IFN levels were detected in the
low virulent infected group compared to the high virulent group in the
fresh water phase [138]. The data imply that high and low virulent
IPNV strains modulate innate responses in head kidney differently.
However, how these differences between the strains affects the scale
and character of host immune responses warrants further studies.
2.3.4. Innate immunity
Both type I and type II IFNs contribute to protection against IPNV in
permissive cell-lines [140], although in vitro studies have shown that
the antiviral activity by IFNγ is not as pronounced as described for
IFNa1 [64]. At least some of the antiviral activity ascribed to IFNγ may
be due to its ability to increase the transcription of type I IFNs [64].
Prior to the identification of the IFN genes themselves, activation of
functional IFN responses was proven indirectly by measuring the
transcription of ISGs i.e. the Mx gene [141], Mx protein [142] or Mx
promotor activation [143]. Early studies measuring Mx protein levels
suggested lack of IFN responses in IPNV infected salmonid cell-lines
[142]. However, in later studies, augmented IFNa1 mRNA were de-
tected in different IPNV infected cell-lines [59,144,145] and in
Fig. 1. Type I interferon signal pathway and evasion strategies for some salmon viruses. (A) Cells sense virus dsRNA and ssRNA via pathogen recognition
receptors (PRRs), RIG-I, MDA-5, TLR3/7/8/19/22. These receptors activate their adaptor molecules IPS1, TRIF and MyD88, which initiate the signaling cascades that
activate IRF3, IRF7 and NF-kB. The evasion mechanisms of IPNV include impairment of IPS1 signaling by VP2, VP3, VP4 and VP5 [153]. All the four IPNV proteins
act on IRF3 and IRF7, while only VP2, VP3 and VP5 act on NF-kB. ISAV segment 7 and ISAV segment 8 inhibit salmon IFN promoter activation in the cytoplasm and
nucleus, respectively [104,105]. PRV Sigma 3 [228] and IPNV VP3 have RNA-binding capacities [123], and may hinder recognition of the viral RNA by PRRs. (B)
Binding of type I IFN to their receptors activates the JAK/STAT signaling pathway. Specifically, Tyk2 and Jak1 kinases activation results in the generation, phos-
phorylation and assembly of the trimeric ISGF3 complex, which consists of a STAT-STAT2 heterodimer and IRF9. This complex translocate to the nucleus, binds to
IFN-stimulated elements (ISRE) and induces ISGs production. IPNV VP4 and VP5 and ISAV Segment 7 are shown to reduce Mx promoter activation [145], suggesting
that ISG functions might be impaired. So far, which host molecules in the signaling cascade that are targeted by these virus proteins are unknown.
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cultivated trout head kidney macrophages [144]. An explanation to
these contradicting results is provided by Skjesol et al. [145], showing
that IPNV possess strategies to antagonize IFN-induced responses by
weakening IFN-signaling and thereby ISG expression.
In vivo, increased levels of PRRs, type I IFNs and several ISGs have
been perceived in Atlantic salmon challenged by both virulent and
avirulent IPNV strains, during acute and persistent infections
[146–149]. In the study by Skjesol et al. [146], coordinated induction
of RIG-I, MDA5, TLR8, TLR9, PKR, MyD88, IFNa1 and IFNc, and several
ISGs were detected in the head kidney (Table 2), however, at sig-
nificantly lower levels in the avirulent IPNV infected fish [146]. Com-
pared to the virulent strain, lower virus load and mortality appeared in
the avirulent strain, suggesting that the immune gene expression levels
are directly related to the rate of virus of replication [146]. A sub-
sequent study has confirmed that the levels of IFNa1 and Mx tran-
scription in different target organs for the virus correlates with virus
load and pathology [150].
The process where juvenile salmon undergo parr-smolt transfor-
mation is a stressful stage in the production cycle, and for IPNV-infected
Atlantic salmon stress can induce a delay in the transcription of immune
markers [151,152]. Julin et al. [138] supported this notion, as Mx
mRNA levels in the infected fish dropped during the fresh water stage,
while transfer to sea provoked reappearance of IPNV for both high and
low-virulent IPNV. In seawater, a long-term expression of Mx was de-
tected over a period 19 weeks and correlated with the IPNV levels
[138]. However, as the results demonstrate, high levels of Mx does not
necessarily correlate with protection.
Since IFN treatment [64] or induction [141] inhibits IPNV replica-
tion, the virus depends on strategies to modulate IFN activity to be able
to establish an infection in its host. Lauksund et al. [153] identified the
proteins preVP2, VP3, VP4 and VP5 as powerful inhibitors of IFNa1
activation through the RIG-I/MDA5 signaling pathways. RIG-I and
MDA5 interact with the adaptor protein IPS-1 upon binding viral RNA,
which activates the transcription factors IRF3, IRF-7 and NF-κB re-
sulting in initiation of type I IFN transcription [154] (Fig. 1A). Although
all four segment B encoded proteins inhibited IPS-1 mediated activation
of the IFNa1 promoter [153], the protease VP4 showed the strongest
inhibition and abolished the promoter activation. However, VP4 mu-
tated to eliminate the protease activity retained its ability to inhibit IPS-
1 activation, proposing that protease activity of VP4 is not mediating
this effect. In contrast to the segment B encoded proteins, the viral
polymerase VP1 showed IFN inducible properties [153]. Over-
expression of VP1 alone potently activated the IFNa1 promoter and
increased the activation mediated by IRF1 and IRF3. Furthermore, VP1
combined with the IRFs upregulated IFNa1 mRNA levels and antiviral
activity against IPNV in TO cells. Since VP1 utilize both viral and non-
viral sources for RNA-synthesis in vitro [155], the IFN inducing prop-
erties of VP1 might be due to dsRNA synthesis. In support of this, a VP1
mutant deficient in producing dsRNA abolished VP1 mediated IFNa1
activation [153]. During IPNV infection, RNA synthesized by VP1
might be recognized by PRR and thus trigger IFN activation. This may
force the virus to develop multiple IFN antagonizing mechanisms to
avoid triggering IFN synthesis. The dsRNA binding of VP3 is also pro-
posed as a mechanism for avoiding antiviral host responses [123]
(Fig. 1A).
Besides encoding mechanisms that inhibit the production of IFNs,
IPNV have developed strategies to inhibit responses to IFN as well
[145]. Experimentally, IFNa1 treatment after IPNV infection results in
restrained virus production and in parallel reduced Mx protein levels
[145]. In the same study, protein synthesis of housekeeping genes were
not affected, implying that the results might be representative for other
ISGs as well. Further, when testing the influence of the different IPNV
encoded proteins on Mx-promoter activation in response to IFNa1, VP4
and the non-structural protein VP5 inhibited the activation of this
promoter [145]. The results suggest that these IPNV proteins are able to
circumvent the action of IFN, most likely by targeting JAK/STAT
signaling (Fig. 1B). The exact mechanisms by which IPNV encoded
proteins impairs signaling pathways leading to type IFNa1 or Mx ex-
pression are presently not understood.
In addition to alerting the IFN system at systemic sites, IPNV is
shown to upregulate splenic and head kidney mRNA levels of IL-10, an
anti-inflammatory cytokine, after acute IPNV infection in salmon and in
asymptomatic IPNV carriers [149]. In the same individuals, there was a
lack of induction of the inflammatory cytokines IL-1β and IL-8, and for
IPNV carriers even IL-8 expression decreased. In accordance with this,
other studies have also reported the absence of IL-1β and TNFα in-
duction in tissues from IPNV infected fish [147,156]. IL-10 is a cytokine
with many regulatory functions, and among these the cytokine is
known to modulate the expression of other cytokines [157]. In mam-
mals, IL-10 has a role in regulating immunity to persistent viral infec-
tions [157]. Reyes-Cerpa et al. [149] hypothesized that IPNV-induced
IL-10 creates an anti-inflammatory milieu, which could explain the high
prevalence and persistence of IPNV in salmon.
2.3.5. Adaptive immunity
Vaccination against IPNV in salmonids has a long story and high
survival rates from experimental trials [158] and field [159] have been
reported, however the vaccines available on the market have not fully
prevented IPNV outbreaks in the field. Studies of the protective re-
sponses have demonstrated that IPNV specific antibodies are elicited
[148]. The major neutralization epitopes of IPNV are localized within
VP2 [160–162], and recombinant VP2 alone, DNA vaccines or multi-
valent vaccines including this component are shown to elicit specific
antibodies against the virus [148,163,164]. More recently, an IPNV
vaccination trial including high and low doses of inactivated virus
vaccine revealed unique signatures of the antibody response before and
after IPNV challenge [148]. Upon immunization, antibody levels in the
high antigen group were substantial higher than for the low antigen
group suggesting an antigen dose dependent response. However, upon
challenge 8 weeks post vaccination, no classical secondary immune
response with increased antibody titers were apparent, instead, anti-
body levels in both the vaccinated groups declined [148]. The study
suggest that the antibodies in the vaccinated groups waned due to their
usage in virus neutralization. In addition to neutralizing activity, it is
likely that specific IPNV antibodies opsonize free virus particles or in-
fected cells and thereby stimulate macrophages, induce cytokine pro-
duction and activate cellular responses. Cellular immunity is scarcely
investigated during fish IPNV infections, although the upregulation of T
cells or antigen presenting derived molecules are reported [146]. As
knowledge of cellular immunity directed against IPNV is still sparse,
basic research is needed to identify cells that contribute to cellular ef-
fector functions against this virus and their mode of action in fish.
2.4. Piscine orthoreovirus (PRV)
No virus is more commonly found in farmed Atlantic salmon than
PRV, a member of the family of Orthoreoviruses. PRV infection can cause
heart and skeletal muscle inflammation (HSMI) in farmed Atlantic
salmon, erythrocytic inclusion body syndrome (EIBS) in Coho salmon,
and HSMI-like disease with anemia in rainbow trout [165–168]. Re-
cently, association with jaundice syndrome in chinook salmon and
proliferating darkening syndrome (PDS) in brown trout have been re-
ported as well [169,170]. PRV infection does not necessarily cause
mortality, but its effect on the heart and red blood cells may weaken the
infected fish and make it less tolerant to stress and hypoxic conditions
[171]. Since PRV is near ubiquitous in farmed Atlantic salmon and
HSMI outbreaks are very common in Norway, the virus is considered as
a significant cause of loss. PRV also infects wild salmon, and may cross-
infect between different salmonid species [172].
2.4.1. Subtypes and genome
Orthoreoviruses are non-enveloped viruses with a double protein
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capsid and a segmented dsRNA genome encoding at least eleven pro-
teins [173] (Table 1). Three subtypes of PRV have been identified in
salmonids so far; PRV-1 in Atlantic salmon and Chinook salmon
[165,169], PRV-2 in Coho salmon [167], and PRV-3 in rainbow trout
and Brown trout [166,167,170]. A more distantly related orthoreovirus
have been found in largemouth bass [97]. Most research have so far
been performed on PRV-1 in Atlantic salmon, and this is the subtype
referred to here unless otherwise is stated.
2.4.2. Tissue tropism and pathogenesis
Orthoreoviruses enter target cells either through a receptor-medi-
ated mechanism, or through a combined process of extracellular outer
capsid proteolysis and receptor-independent uptake [174]. The re-
plication cycle is located to the cytoplasm [173]. PRV, like the mam-
malian and avian reoviruses, infect through an intestinal route [175].
Reported target cells for PRV in Atlantic salmon are erythrocytes,
myocytes and macrophages [176–178]. The PRV infection cycle can be
divided into three main phases, where each phase is described in details
in the following paragraphs.
In the acute phase of infection, up to 50% of the red blood cells
contain dark inclusions visible in a light microscope [177,179], and
electron microscopy shows inclusions filled with virus progeny [177].
PRV is also released to high levels in plasma in this phase [168,177]. If
virus release occurs through cell-lysis is unclear. Although hemolysis of
blood cells have been observed in the spleen and head kidney
[169,180], anemia is usually limited in PRV-1 infected Atlantic salmon
[168,171]. In contrast, rainbow trout and Coho salmon develop anemia
upon infection with PRV-2 and PRV-3 [166,167]. In erythrocytes, in-
creased expression of ISGs is associated with decreased PRV protein
production, while PRV RNA remains unaffected [181], indicating
blocking of translation and virus release. The second phase of a PRV
infection occurs from two to eight weeks after infection and the phase is
characterized by heart inflammation and pathology [168,177,182,183].
The heart tissue seems visually unaffected by PRV infection until an
influx of immune cells starts in the epicardium and continues into the
compact layers [182–184], forming the characteristic pathology of
HSMI. The heart can then regenerate, and in experimental studies this
process is usually without mortality, but is a vulnerable phase for fish
exposed to environmental stress [171]. In the Onchorhynchus species,
rainbow trout, Coho, Sockeye and Chinook salmon, PRV infections have
been associated with liver necrosis and jaundice syndrome/yellowish
liver [166,169,185]. In PRV infected Chinook salmon, the liver and
head kidney were more heavily infected by PRV, compared to Atlantic
salmon [169]. The authors suggested that toxicity from excess hemo-
lysis caused the liver injury.
2.4.3. Persistence
The persistent phase of PRV appears to be life-long in farmed
salmon and have been linked to black spot formation in the salmon filet
[178], an economically important quality problem for salmon produ-
cers. The prevalence of PRV in farmed Atlantic salmon reaches
90–100% in many countries [186,187], whereas wild Atlantic salmon
have a prevalence of 10–20% [172]. It has been proposed, although not
proven, that wild Atlantic salmon have the ability to completely era-
dicate a PRV infection as opposed to farmed salmon. It also appears
from experimental infection studies that rainbow trout are capable of
getting rid of an infection by PRV-3 [188]. Orthoreoviruses are also
persistent in mammals, primarily in the intestine where they have been
associated with inflammation and onset of celiac disease [189]. As-
semblies of PRV-infected macrophages have been found in the muscle
tissue, associated with red or melanized (black) spots [178], indicating
that PRV infection of macrophages induce or worsen the formation of
such spots. Macrophages may be where PRV primarily hide from the
immune system during persistence.
2.4.4. Innate immunity
So far, not much is known about the initial mucosal immune re-
sponse to PRV infection upon entering the host. It is shown that PRV
translocates over the intestinal epithelial wall, but is sensitive to en-
zymatic degradation and/or low pH in the digestive system [175].
The erythrocytes have an important role in the initial dissemination
phase of PRV [177,179]. Studies on the erythrocyte transcriptome re-
sponse to PRV infection revealed upregulation of a wide range of innate
antiviral effector genes, and points towards an essential immunological
role of the red blood cells in the initial pathogen sensing and response
[13,179,181], which is in line with findings of others [12,190]. The
erythrocytes respond with an antiviral immune response characteristic
for RNA viruses, and genes encoding proteins involved in direct sensing
of dsRNA are upregulated in correlation with the level of virus, in-
cluding TLRs 3 and 22, RIG-I, and dsRNA-activated protein kinase
(PKR) [13]. For the related grass carp reovirus (GCRV), TLR19, TLR22,
RIG-I and MDA5 have been reported to play roles during infection
[191–193]. The type I IFN pathway is also strong in the erythrocytes.
While the red blood cells isolated from PRV infected salmon produce
IFNa1 for several weeks [13], the IFNa1-production in cultured ery-
throcytes lasts only for days [179]. Furthermore, the expression of the
IRFs 1, 7 and 9 and mediators of the JAK-STAT signaling pathway genes
are also induced in correlation with expanding PRV levels. Upon GCRV
infection, IRF7 was shown to be phosphorylated and dimerize with
IRF3, indicating that upregulated IRF7 may potentiate the response to
PRV infection [193]. PKR, ISG15 and Viperin were all strongly induced
in concert with levels of infection [13,181]. These ISGs are previously
shown to control production of mammalian orthoreoviruses at the
translational and posttranslational level [194,195]. When this blockage
occurs, the first phase of virus progeny production ends [181]. The
mammalian orthoreoviruses counteract the antiviral response by
binding and inactivating IRF3 and thereby blocking IFN production and
ISG expression [196]. The long lasting transcription of IFN-regulated
genes in PRV-infected salmon does not indicate a blockage of IFN sig-
naling. MRV is also reported to block host translation through inter-
action with PKR and inhibition of stress granule formation [197]. This
is in line with the translational inhibition observed in PRV-infected
erythrocytes. However, MRV is shown to bypass the host translational
block and continue its own virus protein production [197], which does
not seem to be the case for PRV.
Coho and Sockeye salmon mount a limited innate immune response
to PRV-1 when compared to the Atlantic salmon [198,199]. Similarly,
Atlantic salmon respond less to PRV-3 compared to rainbow trout
[188], indicating that the antiviral response is stronger in the host that
suffer the most severe pathological outcome. This implies PRV-medi-
ated pathology could be coupled to its ability to induce antiviral im-
mune responses in the host. According to transcriptome data, the innate
immune response in erythrocytes continues through the second phase
of infection [13]. This long-lasting innate immune response may ex-
plain the observed cross protection against unrelated secondary viral
infections (SAV and IHNV) that last (for) many weeks after infection
with PRV [200–202].
2.4.5. Adaptive immunity
According to detection of PRV RNA in different organs after infec-
tion, PRV accumulate in the spleen after the peak phase in blood [177].
Fish erythrocytes were recently reported to go into a shape-shifted
phase where they express both MHCI and MHCII, indicating that they
may present both intra- and extracellular antigens [203]. This shape-
shifting may drive accumulation of infected erythrocytes in the spleen
following PRV infection. However, macrophages may also engulf the
PRV-infected erythrocytes (hemophagocytosis) and serve as PRV an-
tigen presenting cells.
Using bead-based multiplex immunoassays, PRV specific IgM tar-
geting both outer capsid proteins and intracellular virus factory pro-
teins of PRV have been detected in plasma [204]. This specific humoral
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response against PRV is induced at the end of the HSMI phase. Small
differences in antibody kinetics are observed for the different PRV
proteins [204].
The HSMI hearts primarily recruit CD8+ T cells [183], but tran-
scriptomic data indicate that also helper T cell, macrophage and B cell
levels increase after disease onset [53,183]. The increase in CD8+ cells
is associated with elevated granzyme A mRNA levels, which indicates a
cytotoxic T cell attack on PRV infected heart cells [53,183]. The im-
mune cell recruitment parallels decreased virus levels in the heart,
suggesting an immunological attack specifically directed against virus-
infected myocytes [177,182].
After PRV infection, there is an increase in soluble and membrane-
bound IgM transcripts in the head kidney, while CD8 and granzyme
mRNAs are induced in the spleen [205]. This may represent pro-
liferating Be and cytotoxic T-cells in head kidney and spleen, respec-
tively. No obvious differences in cytokine/chemokine patters have been
reported in spleen and head kidney, apart from an increased upregu-
lation of the chemokine CCL19/MIP-3β in spleen [205]. CCL19 is a
chemokine reported to attract dendritic cells, and T- and B cells that
express the chemokine receptor CCR7 [19,206]. Presently, the role of
CCL19 is not defined in salmonids.
The specific adaptive immune response elicited in PRV infected fish
implies that effective vaccines can be developed, and recently a vaccine
based on inactivated PRV particles was reported to protect from HSMI
[207].
2.5. Piscine myocarditis virus (PMCV)
PMCV is associated with cardiomyopathy syndrome (CMS), a dis-
ease that kills large farmed Atlantic salmon in seawater. CMS is char-
acterized by inflammation and necrotic damage in the atrium and
ventricle, which can lead to by sudden death and heart rupture [208].
2.5.1. Subtypes and genome
PMCV is a simple, non-enveloped dsRNA virus belonging to the
family of Totiviridae (Table 1). The PMCV dsRNA genome encodes three
proteins, in contrast to most other totiviruses that encode only two [30].
A related virus that also encode a third protein, have been found in
Golden shiner [209], and along with PMCV, these are the only variants
shown to infect vertebrates. This third protein (ORF3) may therefore
play a role in virus dissemination within higher organisms.
2.5.2. Tissue tropism and pathogenesis
The atrium is where pathology initially occurs [210]. The amount of
PMCV in the heart is directly associated with the pathological changes,
and the peak in PMCV-levels corresponds with the pathology both in
time, and in the localization within the specific microscopic sites of
necrosis and inflammation [30,210–212]. Existing data indicate that
the heart is the primary target organ for PMCV replication, and ac-
cordingly, high virus levels are present in the heart at the peak of in-
fection and disease [30,211]. PMCV origin and transmission pathways
are not well understood [213].
2.5.3. Innate immunity
The immune response to PMCV have been explored using micro-
arrays [211] (Table 1), and is characterized by a typical antiviral, IFN-
mediated immune response in the first two weeks after infection, which
dominate in blood cells, spleen and kidney. The antiviral response re-
sembles that of PRV, and includes expression of dsRNA sensors like RIG-
I and TLR3, and antiviral effectors like Mx and Viperin together with
IFN signaling mediators like STAT1 [211]. However, in contrast to PRV,
the response to PMCV levels off after a couple of weeks, whereas the
virus levels keep increasing until pathology develop in the heart several
weeks later. IgM transcripts was observed in the heart already at 4 wpc,
which could potentially represent an “innate” B cell response. The in-
nate-like Be and myeloid-cell expressed protein CD9, also named
tetraspanin, was strongly induced in heart at 4 wpc, which coincided
with a decreased antiviral response. CD9 is known to be involved in
intracellular mobilization of viruses, including their mechanisms of
entry and exit [214]. The levels of CD9 expression in this study corre-
sponded with the increase in PMCV levels [211]. Likewise, when the
virus levels plateaued from 6 wpc, CD9 transcript levels decreased as
well. The putative role of CD9 in PMCV infection and dissemination
warrants further exploration. In PMCV infected salmon elevated IFN
responses was observed in the red blood cells and appeared to last
longer in the blood compared to other tissues [211]. However, the red
blood cells were not found to be infected by PMCV.
2.5.4. Adaptive immunity
The pathology of the heart is associated with a corresponding strong
immune cell recruitment and upregulation of adaptive immune gene
expression [211]. Immunoglobulin transcript levels in heart, indicating
B cell recruitment, increased in line with the progression of CMS pa-
thology. A microdissection study on the CMS lesions revealed higher
levels of PMCV, MHCII-, Be and T-cells transcripts in the lesions
compared to the surrounding unaffected tissue [212]. This indicates
that the immune cell response in the heart targeting the virus occur at
late time points, and include both cellular and humoral elements.
The complement components C1, C3, C5 and C8 were also expressed
in the heart prior to the immune cell influx, and the authors suggested
that complement mediated responses initiate inflammation and pa-
thology [211]. A similar complement expression was observed in the
spleen.
3. Towards better understanding of virus-host interactions and
antiviral immunity?
3.1. Type I IFN responses and antiviral ISGs
Of the known piscine ISGs, not so many have been characterized in
vitro or in vivo for their contribution to antiviral immune responses. For
example, only a few of them have been tested for their ability to inhibit
virus replication [215–217]. Clearly, more work needs to be done to
uncover additional bony fish ISGs and their properties including their
antiviral mechanisms. For viruses infecting mammalian hosts and in
particular viruses infecting humans and mice, a variety of approaches
have been employed to identify ISGs with antiviral activities and how
their functions are directed against the virus [218–220]. A novel
method for identifying large numbers of antiviral genes has been de-
scribed based on virus infection of cells, which over-express fluorescent
labelled ISGs their ability to inhibit virus replication [221]. Antiviral
activity is measured by analysis of fluorescent-labelled viruses and ISGs
by flow-cytometry. A similar approach could be used to identify genes
with antiviral activity against fish viruses. For SAV and infectious he-
matopoietic necrosis virus (IHNV), GFP-expressing strains exist that can
be directly used for this purpose [44,222]. In addition, in vitro studies
using gene knockouts in mice have been useful to detect their pheno-
type [223]. However, deleting a single ISG from a large pool of IFN-
induced genes carries an inherent risk of not detecting an antiviral
phenotype due to the redundancy of the IFN system. Via the recent
CRISPR/Cas9 technologies, B. Collet and collaborators have disrupted
proteins taking part in IFN signaling to uncover their effects on ISG
expression [224]. CRISPR/Cas9 or other gene knock-down strategies
should be further implemented for studies on ISG functions in fish. As
described for IPNV, type I IFNs and ISGs may affect virus persistence
[138,225], additionally, they may have roles in virus pathogenesis
[226]. Further insight into the effects IFNs and ISGs have on teleost fish
could extend our understanding of how these molecules contributes to
viral disease outcomes in vivo. Moving forward, new approaches to
understand this broad functionality of the IFN system will be needed.
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3.2. ISG levels do not necessarily correlate with protection
It is a paradox that the highest ISG levels in viral infected fish often
are detected in parallel with the highest virus levels [51,53,146], which
implicates that these effectors have not been able prevent virus re-
plication and the establishment of the infection. Virus countermeasures,
where the viruses hamper host ISG responses, might partly explain this.
It is also possible that these transcripts are not efficient translated and
as a result, their mRNA levels do not reflect the amount of protein
produced. While ISG levels are frequently measured in the systemic
immunological organs and/or target organs for the virus, the host-virus
dynamics at virus entry points (i.e. gills and fins) are neglected. How-
ever, these initial meeting points might be key arenas to help limit the
internal spread of viral infections through alerting IFNs and other cy-
tokines. In addition, other constitutive or innate barriers that do not
rely on new protein synthesis are of importance for the disease re-
sistance. These topics warrant further investigations.
3.3. Interferon evasion strategies; the viruses take the stage
One of the first obstacles a virus meet when infecting a host is the
IFN system and therefore successful viruses have evolved multiple
strategies to antagonize the system [227]. Some of the effects mediated
by fish viruses are summarized in Fig. 1, and as shown, there are studies
demonstrating that salmonid viruses may inhibit the synthesis of IFNs
by targeting the IRFs or block IFN activated signaling mediated by JAK-
STAT signaling pathways. Since type I IFNs are produced directly as a
response to dsRNA molecules that are sensed by PRRs of infected cells,
many viruses produce dsRNA binding proteins to sequester these signals
[227]. IPNV VP3 and PRVSigma 3 are examples of viral encoded ds-
RNA binding molecules [123,228], however, their direct effects on IFN
induction remain to be clarified. In general, for most of the studies
performed in fish, the molecular mechanisms that these viruses use to
target host proteins are not examined in very much details and should
be further investigated. A family of host proteins named suppressors of
cytokine signaling (SOCS) have also been shown to be a target for viral
exploitation [229]. The SOCSs, in particular SOCS1 and SOCS 3 that are
ISGs themselves, negatively regulate JAK/STAT signaling. Atlantic
salmon SOCS1 has been demonstrated to be a negative regulator of both
type I and type II IFN signaling in salmonid cell-lines [230]. Both SAV3
and IPNV are able to modulate SOCS expression in TO cells, and SAV3,
especially, induce an early robust SOCS1 expression, which may re-
present a putative strategy to promote viral survival [231].
3.4. In fish, red blood cells are also immune cells
The role of salmonid red blood cells in the immune response to viral
infections is only in its first stage of being explored. Nevertheless,
several immune functions have been assigned to red blood cells; they
express nucleic acid sensing PRRs [12], components of the IFN sig-
naling system and a large array of ISGs [12,13]. They are themselves
primary target cells for PRV infection and replication [13,177,188], and
can take up ISAV by endocytosis [232]. Red blood cells also respond to
viruses when they are not infected, including PMCV in Atlantic salmon
[211], and IPNV and viral hemorrhagic septicaemia virus (VHSV) in
trout [203,233]. Expression of MHCI and eII on red blood cells, in-
dicate their ability to present antigen [190]. The red blood cells have
been shown to differentiate and change shape when responding to in-
fections and heat stress [179,203], and produce pro-inflammatory cy-
tokines like IL-1β, IL-8 and IFNγ in response to IHNV [203]. Surpris-
ingly, red blood cells significantly induce the expression of IgM in this
differentiated state [203]. These findings indicate that the red blood
cells in fish have the potential to acquire features that resemble both
monocytes and B cells. Typical red blood cell characteristics, like the
level of haemoglobin, are reduced in this state [203], and in PRV in-
fected Atlantic salmon the haemoglobin loss is associated with
increased sensitivity to hypoxic stress [171]. The role salmonid red
blood cell differentiation play in a virus-infected fish is a fascinating
new research field.
3.5. Humoral and cellular immunity to salmonid viruses – how do they take
the stage?
Secreted IgM specific for viral proteins along with virus-neutralizing
activities in serum have been shown to develop in salmon after infec-
tions with IPNV, SAV, PRV and ISAV [71,204,234,235]. In line with
this, vaccine effects are strongly associated with specific antibodies for
SAV and ISAV [109,111,236,237], while for IPNV a clear correlation
between virus clearance and the levels of antibodies is questionable
[164]. Virus outer capsid proteins represent the most relevant targets
for neutralizing and protective effects. SAV E2 [237,238], ISAV HE
[239] and IPNV VP2 [160], are considered the primary neutralizing and
protective antibody targets. For PRV and PMCV, neutralization assays
have not been established due to the lack of susceptible cell cultures to
test the effects on. However, multiplex bead-based immunoassays have
been used to identify PRVμ1 as an outer capsid target for specific IgM
[204]. The bead-based immunoassays also revealed that the non-
structural PRV protein μNS, only expressed in virus replicating cell, is
an additional antibody target [204]. Likewise, humans infected by the
ssRNA-viruses Dengue virus and Zika virus produce antibodies tar-
geting the nonstructural protein NS1 [240], which was identified a
vaccine component that promoted protection against Dengue fever
[241]. Further exploration of non-structural virus proteins as antibody
targets could be of great value for fish vaccine design.
Complement proteins are likely to be involved in the IgM-mediated
immunity in fish, and a coordinated expression of IgM and complement
factors have been shown for SAV and PMCV infection [211,242]. The
role and importance of complement in antibody-mediated protection in
fish should be better established, clarifying if complement-mediated
cytotoxicity and cell lysis directed by IgM are central mechanisms.
Long-lived plasma-cells in head kidney are proposed to be re-
sponsible for the specific antibody production after infection [243].
Furthermore, enrichment of certain clonotypes of both IgM and IgT
have been shown to develop in spleen from rainbow trout after infec-
tion with VHSV, indicating general proliferative B cell responses in
spleen in the early phase [16]. Activation-induced cytidine deaminase,
an enzyme linked to Ig hypermutation, was found in head kidney
melanomacrophage centers of channel catfish, indicating that antibody
specificity may develop there [244]. In addition, the B cells in teleost
possess properties of innate-like B-1 cells like phagocytosis and CD5
expression [18,21–23,245]. In salmonids, B cells express a range of
TLRs [19,20], and respond to the TLR-ligand CpG by differentiating
into antibody-secreting cells, up-regulate co-stimulatory molecules and
IFNa1 transcripts [19]. Whether all B cells have remained both typical
innate and adaptive functions, or the properties belong to separate
subpopulations, need to be determined. A tissue-specific B cell re-
sponse, primarily linked to expression of soluble and membrane bound
IgM, are demonstrated in hearts infected with SAV, PRV and PCMV
[52,53,211], even at early time points post infection. Interesting
questions that arise are how these local B cell are activated and re-
cruited and how they mediate their protective responses. Activation of
the B cells directly by viral PAMPs or early innate signals including type
I IFNs and other inflammatory cytokines may modulate B cell re-
sponses, both by acting directly on the B cells or indirectly via signaling
to DC and other cells. Future work should aim at further characterize
how the innate-like and adaptive qualities of teleost B cells play to-
gether in mediating protection against viruses. T cell responses, their
functions and how they co-ordinate their activities with other leuko-
cytes during viral infections are not completely understood in teleosts.
As described in earlier sections, transcriptome analyses indicate that
CD4+ and CD8+ T cells together with some of their signature cytokines
and effector molecules are evoked by the viruses covered here
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[53,98,211,246]. Taken together, the data indicate that T cells multiply
primarily in the spleen and in the target organs for the virus. For SAV,
PRV and PMCV infections, CD8+ T-cells and cytotoxicity genes increase
in association with heart inflammation and pathology [52,53,183,211].
This also leads to a reduction in virus levels in heart, which suggest that
cytotoxic T cells responses are implicated in protection. Laser-capture
microdissection of CMS heart lesions led to findings indicating a direct
co-localization between pathological sites, virus-infected cells and cy-
totoxic T cells, which points to very specific interactions between target
cells and T cells that result in cell death [212]. This is in line with other
studies that identify cytotoxic T cells in teleost fish as mediators of
adaptive immunity [26]. The dual role of T cell cytotoxicity observed in
heart infections with SAV, PRV and PMCV where CD8+ T cells are
associated with antiviral-, but at the same time pathological effects,
needs further study.
Even though progress has been made in recent years regarding the
description of bony fish T cells, most of these findings are inferred on
the basis of gene expression. For rainbow trout, mAbs against different
CD4-1, CD4-2, and CD8a and CD8b are available, and have been used to
identify different T cell subtypes [25,247]. It is noteworthy that CD4
and CD8 molecules are not only expressed on T cells, but also on other
cell types, e.g. CD4-2 is also expressed in trout monocyte-like cells
[247]. Therefore, multiple markers should be used for true identifica-
tion of T cells. Although signature cytokines and transcriptions factors
for different Th subsets are identified in salmonids, their functions are
modestly explored. The salmon Th2 cytokines IL-4 and IL-13 were
found to increase the number of IgM secreting B cells in vivo [27].
For further development in this field, development of new specific
markers and tools is a requisite to pave the way for identifying which T
cell subsets that contribute to cellular antiviral immunity in fish. Also
identification and separation of lymphoid innate T cells and NK cells are
essential to understand the major cell types involved in antiviral cell-
mediated immunity.
3.6. Persistent virus infections - a game of hide and seek
Viruses have developed many different strategies to survive and to
propagate in a susceptible host. One of them is to remain in a latent
phase in the cell with very slow replication and with very little or no
virus release, which represents the characteristics of persisting viruses
[248]. Understanding the virus-host interplay that leads to a persistent
infection requires detailed knowledge of their collective rendezvous.
For three of the viruses described in this review, namely IPNV, PRV and
SAV, there are reports suggesting that they may persist in their host
[47,249], even throughout their lifespan [130,178].
As described in an earlier section, IPNV multiply in head kidney
adherent leucocytes, most likely macrophages [133]. Johansen et al.
[133] demonstrated that about 1% of the total head kidney leukocytes
were infected by IPNV, while higher numbers were reported by Munro
et al. [250]. PRV infections in Atlantic salmon also develop into lifelong
persistence, and macrophage-like cells are proposed to be the main cell
type for this persistence [178]. In contrast to the PRV-1 persistence in
farmed Atlantic salmon, the PRV-3 variant in rainbow trout appears to
be cleared from the hosts, at least in experimental studies [188]. For the
related mammalian orthoreovirus, persistence have been linked to
mutations in outer capsid proteins of the virion, allowing the virus to
bypass steps in the uncoating process needed for cytoplasmic transfer
upon infection [251]. However, whereas MRV is sensitive to IFN type I,
is PRV produced at high levels despite IFN signaling [13].
In mammals, therapeutic vaccines against persisting viral infections
have been developed with varying success [252]. Muang'andu et al.
[253] reported that vaccine generated antibodies were not sufficient to
clear persistent IPNV infections and that vaccination did not prevent
the fish from becoming viral carriers. Many viruses possess strategies
for cytokine evasion to facilitate persistence by interfering with normal
cytokine signaling and leucocyte trafficking [248]. In mammals, a suite
of cytokines are targets for viral subversion including type I IFNs and IL-
10 [157]. As discussed in an earlier section, these cytokines are sug-
gested to be important for the establishment and maintenance of IPNV
persistence [149]. In line with this, Saint-Jean et al. [225] found that
IFN responses might be involved in retaining IPNV persistence. Simi-
larly, the IL-10 receptor was upregulated in PRV infected erythrocytes
along with SOCS1 [13].
Programmed cell death (apoptosis), is a host mechanism to get rid of
virus-infected cells. On contact with cytotoxic T cells and NK cells, cells
can be killed by granzyme granules, but also by TNF and Fas ligands.
These effectors engage proteolytic caspase cascades that leads to
apoptotic cell death. Viruses may encode both pro- or anti-apoptotic
proteins, and blocking the apoptotic system may represent a positive
strategy for virus survival. For IPNV, virus induced apoptosis in infected
cell-lines [254,255] and infected fish [254] has been reported. IPNV
VP5 shares homology with members of the anti-apoptosis Bcl-2 family
[256], which functions is to block caspase activity and enhance viral
progeny production. When overexpressed in cell lines VP5 show an
anti-apoptotic potential [256]. In contradiction to this, Santi et al.
[254] by the use of recombinant IPNV Sp strains demonstrated that the
VP5 protein had little influence on apoptosis both in vitro and in vivo.
The study concluded that VP5 was not essential for the establishment of
a persistent IPNV infection. However, it should be noted that in tissues
of IPNV-infected fish there is only a small number of cells that are
apoptotic [156]. Interestingly, in IPNV-positive peripheral blood, head
kidney and spleen leukocytes from infected rainbow trout no apoptotic
nuclei were found [257]. Assuming that IPNV-positive macrophages are
present in these cells, a possible explanation for the lack of apoptotic
morphology in these cells is that differentiated macrophages, as long-
lived cells, are resistant to various death stimuli. It is also possible that
persistent infections of macrophages are accompanied with specific
inhibition of host-induced apoptosis, which may delay cell death and
facilitate viral persistence in these cells.
Both in field trials [249,258] and in experimental SAV challenge
experiments [47] the clearance of the virus is not absolute, suggesting
that surviving fish may become life-long asymptomatic carriers. In the
field trial, viral RNA were detected over a period of nine months and
the highest levels, at the latest time points, were found in gill, followed
by heart and pancreas [249]. However, attempts of virus isolation from
tissue pools in support of carriers were unsuccessful beyond day 71. To
our best knowledge, there are no reports of productive in vitro infec-
tions of subsets of salmonid leukocytes with SAV.
While progress has been made, there are still remaining questions
surrounding viral persistence in fish. For IPNV and PRV, macrophage-
like cells are suggested as the main reservoir for persistent virus
[133,178]. Macrophages are professional phagocytes specialized in
pathogen elimination and antigen presentation, functions the virus may
have to suppress to be able to persist. By modulating cytokine secretion,
reducing antigen presentation and interfering with cell-death, viruses
may functionally impair immune cells for their own benefit.
3.7. Preventing viral disease – success so far?
A range of vaccination strategies have been tested against the viral
diseases covered here [69,110,207,259–264], and vaccines targeting
IPNV, ISAV and SAV have reached the market. Even if several of the
vaccination trials performed have been reported as successful, the
vaccines have not given complete protection against viral disease in the
field. There could be several reasons for this, like suboptimal antigen
doses or adjuvant effects, immunosuppressed hosts, the inability to
induce mucosal protection, and/or lack of T-cell mediated responses to
the vaccine. New strategies like the IFN adjuvanted DNA vaccines
tested against ISA [109,265], or the oral vaccines with viral antigen
carried by commensal bacteria tested against IPN [266], could provide
more optimal solutions in the future. Another approach to prevent viral
diseases in aquaculture is breeding for resistance, which have
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successfully reduced IPN in Atlantic salmon [101]. Gene editing will
most likely put this strategy on fast forward. However, there might be
risks related to a rush to put moderately protective vaccines and partly
resistant genetic families to the market. For example, if the virus still
has the ability to infect and replicate in the fish, there is a possibility
that the virus may adapt, circumvent the resistance, and revert to
virulence. An additional approach is to counteract immune suppression
and optimize antiviral immune activity using immune-stimulating and
immune-optimizing feed [267–269].
4. Concluding remarks
Studies of important virus infections in salmonid aquaculture reveal
the need to expand the understanding of the timing and tissue locali-
zation of immune activation, the role of viral persistence mechanisms,
how erythrocytes contribute to innate immunity, and the requirements
for T cell based long-term protection. However, studies on fish immune
cell populations and their activity are still hampered by the shortage in
available cell population marker antibodies and other immunological
tools. A joint effort to develop the critical tools will help advance the
understanding of the dynamics of fish antiviral responses.
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